Tilray Medical Welcomes Government of Luxembourg Delegation Visit to European Campus in Portugal
LISBON, Portugal, June 22, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, welcomes the Luxembourg Ministry of Health Delegation to the Company’s European campus and facility located in Cantanhede, Portugal. Tilray’s EU-GMP-certified medical cannabis cultivation and manufacturing facility in Portugal provides patients in Luxembourg and across Europe, where permitted by law, with safe and reliable access to high-quality medical cannabis.
The visit was organized to give the Luxembourg Delegation a firsthand view of Tilray’s EU-GMP operations in Portugal, the premiere medical cannabis site in Europe. The delegation included:
- Paulette Lenert, Deputy Prime Minister and Minister of Health of Luxembourg
- H. E. Conrad Bruch, Ambassador of Luxembourg to Portugal
- Alain Origer, National Drugs Coordinator
- Laura Valli, International Affairs Coordinator
- Bob Lessel, Social Health Department
- Sven Back, Department of narcotics and medicinal cannabis
Sascha Mielcarek, Tilray’s Managing Director in Europe, said, “We are honored to host the Luxembourg Ministry of Health Delegation at our state-of-the-art cannabis facility in Cantanhede, Portugal. Demand for cannabis legalization in Europe is growing rapidly and we are incredibly proud to service the patients in Luxembourg and around the world with the high-quality medical cannabis products they rely on and in the formats they prefer.”
Tilray has a pioneering track record as a company committed to producing the highest-quality cannabis products available to consumers and patients in need around the world and was the first to successfully export medical cannabis from North America and import medical cannabis products into the EU in 2016.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, and Symbios. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.
About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time. Tilray Brands delivers on this mission by inspiring and empowering the worldwide community to live their very best life and providing access to products that meet the needs of their mind, body, and soul while invoking wellbeing. Patients and consumers trust Tilray Brands to deliver a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we open a world of wellbeing, visit www.Tilray.com.
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: expectations regarding the performance and scale of the Company, including Tilray Medical; and the Company’s ability to expand its offering to patients worldwide, including via Tilray Medical. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/56cca4b1-684d-402b-ab7b-1c3f2ca19509To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Cool Company Ltd. – Formation Completed1.7.2022 18:46:54 CEST | Press release
Golar LNG Limited ("Golar") announces today that it has sold to Cool Company Ltd. (“CoolCo”) the management organization responsible for the technical and commercial management of LNG carriers, and the provision of such services to third parties, as contemplated in the January 2022 Cool Company Ltd. formation update. CoolCo paid the previously agreed purchase price of $5 million in cash for the shares plus $1.5 million in working capital. As part of the transaction, approximately 600 maritime and office-based personnel became CoolCo employees. Today, Richard Tyrrell also assumed his position as CEO of CoolCo, replacing Interim CEO Karl Fredrik Staubo. FORWARD LOOKING STATEMENTS This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended) which reflects management’s current expectations, estimates and projections about its operations. All statements, other than statements of historical facts, that address activitie
Cool Company Ltd. - Formation Completed1.7.2022 18:37:43 CEST | Press release
Cool Company Ltd. ("CoolCo" or the "Company") is pleased to announce today that it has acquired from Golar Management (Bermuda) Limited the management organization responsible for the technical and commercial management of its LNG carriers and the provision of such services to third parties, as contemplated in the January 2022 Cool Company Ltd. formation update. CoolCo paid the previously agreed purchase price of $5 million in cash for the shares plus $1.5 million in working capital. As part of the transaction, approximately 600 maritime and office-based personnel become employees of CoolCo. Today, Richard Tyrrell also assumed his position as CEO of CoolCo, replacing interim CEO Karl Fredrik Staubo. Richard Tyrrell commented: “CoolCo is delighted to formally welcome the members of the Golar LNG team that provide first class technical and commercial management services to our owned fleet of eight LNG carriers, in addition to providing such services to 20 third party vessels. The acquisi
U.S. Government Orders Additional Monkeypox Vaccines from Bavarian Nordic1.7.2022 16:00:10 CEST | Press release
Bavarian Nordic to supply an additional 2.5 million doses of JYNNEOS® vaccineDoses will be manufactured using existing bulk vaccine from previous orders from BARDADeliveries starting in the fourth quarter of 2022 with the majority to be delivered in 2023 COPENHAGEN, Denmark, July 1, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has ordered an additional 2.5 million doses of liquid-frozen JYNNEOS®, a non-replicating smallpox vaccine and the only FDA-approved vaccine against monkeypox. Deliveries under this contract will start in the fourth quarter of 2022 and continue through early 2023. This order comes a few weeks after an order from BARDA for the delivery of 500,000 doses of the vaccine in 2022 in response to the current monkeypox outbreak. With a previous order from BARD
Den amerikanske regering bestiller yderligere vacciner mod abekopper fra Bavarian Nordic1.7.2022 16:00:10 CEST | pressemeddelelse
Bavarian Nordic skal levere yderligere 2,5 mio. doser JYNNEOS® vaccineRåvaccine, produceret under tidligere kontrakter med BARDA, vil blive anvendt til færdigproduktion af doserneLeverancerne vil starte i fjerde kvartal 2022 og fortsætte ind i 2023, hvor hovedparten af doserne vil blive leveret KØBENHAVN, Danmark, 1. juli 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at Biomedical Advanced Research and Development Authority (BARDA), en del af Office of the Assistant Secretary for Preparedness and Response ved U.S. Department of Health and Human Services, har bestilt yderligere 2,5 mio. doser af den flydende-frosne udgave af JYNNEOS®, en ikke-replikerende koppevaccine, og den eneste FDA-godkendte vaccine mod abekopper. Leverancerne vil starte i fjerde kvartal 2022 og fortsætte ind i begyndelsen af 2023. Denne ordre er afgivet få uger efter en anden ordre fra BARDA på levering af 500.000 doser af vaccinen i 2022 til brug i forbindelse med det aktuelle udbrud af abekopper. Med en
Incap Corporation: INCAP GROUP’S HALF-YEAR FINANCIAL REPORT FOR JANUARY–JUNE 2022 AND WEBCAST 28 JULY 20221.7.2022 14:30:00 CEST | Press release
Incap Corporation Press release 1 July 2022 at 3:30 p.m. EEST The corrected release includes the time of the webcast. Incap Group’s half-year financial report for January–June 2022 will be published on Thursday, 28 July 2022 at approximately 09:00 a.m. Finnish time. At that time, reporting materials in Finnish and English will be available on the company's website at https://incapcorp.com/reports-and-presentations/. Webcast The company will hold a webcast on Thursday, 28 July 2022 at 2:00 p.m. EEST. The result will be presented by Otto Pukk, CEO, and Antti Pynnönen, CFO, Incap Corporation. In addition to the result, Incap's UK operations will be presented at the event, and Jamie Maughan, Director of Operations UK will participate in the event. The live webcast can be followed at https://incap.videosync.fi/2022-07-28-half-year-report. During the webcast, the public can ask questions in the chat room at the address mentioned above. The recording of the broadcast will be available on the